Given the role of HDAC5 in modulating the expression PD-L1 in pancreatic cancer cells, we next assessed the potential clinical benefit of HDAC5 inhibition in pancreatic cancer patients treated with ICB. This evidence concerns the gene CD274 and familial pancreatic carcinoma.